|
Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy. |
|
|
Honoraria - Astellas Pharma |
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Carrick Therapeutics; Clovis Oncology; Clovis Oncology; Ferring; Ferring; Hinova Pharmaceuticals; Hinova Pharmaceuticals; Janssen; Merck Sharp & Dohme; Novartis; Pfizer |
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); eFFECTOR Therapeutics (Inst); Emergent BioSolutions (Inst); Ferring (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Carrick Therapeutics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer |
|
|
Employment - Surface Oncology |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech; Jounce Therapeutics; Merck; Michael J. Hennessy Associates; Novartis; Ology Medical Education; Pfizer |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Endocyte (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst); Sotio (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Genentech |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
|
|
|
Honoraria - Astellas Pharma; Bayer; Clovis Oncology; Janssen |
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; Janssen |
Speakers' Bureau - Astellas Pharma; Bayer; Clovis Oncology; Janssen |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Pfizer; Sanofi; Seattle Genetics/Astellas |
Research Funding - Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst) |
|
|
Stock and Other Ownership Interests - Roche |
Consulting or Advisory Role - BioProtect |
Research Funding - Bristol-Myers Squibb |
|
|
Research Funding - Astellas Pharma (Inst) |
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst) |
|
|
Honoraria - Astellas Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Speakers' Bureau - Janssen Oncology |
Travel, Accommodations, Expenses - Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Roche/Genentech |
|
|
|
|
|
|
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Sanofi; Steba Biotech; Takeda |
Speakers' Bureau - Amgen; Janssen |
Research Funding - Ferring (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi |
|
|
Stock and Other Ownership Interests - Abbvie; Cardinal Health; GlaxoSmithKline; Lilly; PSMA Therapeutics; United Health Group; Varian Medical Systems |
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Myovant Sciences; Myriad Genetics; Novartis; Novartis; Noxopharm; Pfizer; Progenics; Sanofi |
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Merck (Inst); Sanofi (Inst); SOTIO |
Expert Testimony - Sanofi |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi |